CTOs on the Move

SHINE Technologies

www.shinefusion.com

 
Based in Janesville, Wisconsin, SHINE deploys its safe, cost-effective and environmentally friendly fusion technology in a stepwise approach. Its systems are used to inspect industrial components in aerospace, defense, energy and other sectors. SHINE`s proprietary medical isotope production processes create non-carrier-added lutetium-177 and are expected to create molybdenum-99. In the future, SHINE plans to scale its fusion technology to help solve one of energy`s toughest hurdles by recycling nuclear waste. Through a purpose-driven and phased approach, SHINE aims to generate fusion power to deliver clean, abundant energy that could transform life on Earth
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Eli Moll
Chief Operating Officer Profile

Funding

SHINE Technologies raised $30M on 11/27/2018
SHINE Technologies raised $18M on 07/01/2019
SHINE Technologies raised $50M on 10/07/2019
SHINE Technologies raised $150M on 06/28/2021

Similar Companies

Metrics

Metrics provides pharmaceutical product development including pre-formulation studies, formulation development, clinical trial batch manufacturing and clinical trial batch packaging and labeling for non-sterile dosage forms. In addition, Metrics

Teon Therapeutics

Teon Therapeutics is a global start-up bio-pharmaceutical company located in Redwood City, CA.

F H Ayer Manufacturing Company

F H Ayer Manufacturing Company is a Chicago Heights, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arjo

We believe that empowering movement within healthcare environments is essential to quality care. ⚖️ https://t.co/e11hfbUA49

XTuit

XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.